Video: Leading the Alpha Charge – with Øystein Soug

From the Norwegian Air Force to alpha-emitting radiopharmaceuticals, Øystein Soug has taken the unconventional route to biotech leadership

October 28, 2026
1 min

The Medicine Maker

At a Glance

Category	Detail
Condition	Cancers that have spread to the abdominal cavity
Key Mechanisms	Radspherin is a receptor-independent alpha-emitting radiopharmaceutical delivered directly into the peritoneum, intended to concentrate radiation around residual cancer cells while limiting exposure elsewhere in the body.
Target Population	People with cancers that have spread to the abdominal cavity; the article does not specify eligibility criteria.
Care Setting	Radiopharmaceutical development and treatment involving direct intraperitoneal delivery; the article does not specify a clinical care setting.

Key Highlights

Oncoinvent is developing Radspherin for cancers that have spread to the abdominal cavity.
Radspherin uses receptor-independent alpha emission and is delivered directly into the peritoneum.
Øystein Soug discusses lessons from helping bring Xofigo to market.
Manufacturing and supply chains remain challenges for radiopharmaceuticals, according to Soug.
Soug discusses new isotopes, delivery methods, combination strategies, and Oslo’s emergence as a radiopharmaceutical hub.

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

Risks

Patient & Prescribing Data

The therapy is being developed for cancers that have spread to the abdominal cavity; no prescribing or eligibility details are provided.

Radspherin is described as an investigational, receptor-independent alpha-emitting radiopharmaceutical delivered directly into the peritoneum. The article provides no dosing, safety, or efficacy data.